Next 10 |
home / stock / idrsf / idrsf news
2024-03-22 11:49:09 ET Summary Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales of over $2 billion. Despite positive developme...
2024-03-20 16:07:27 ET More on Idorsia Historical earnings data for Idorsia Financial information for Idorsia Read the full article on Seeking Alpha For further details see: Idorsia gets FDA approval for hypertension drug Tryvio
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
2023-10-25 05:47:04 ET Idorsia Ltd (IDRSF) First Nine-Month 2023 Earnings Conference Call October 24, 2023 9:00 AM ET Company Participants Andrew Weiss – Senior Vice President, Head of Investor Relations & Corporate Communications Jean-Paul Clozel –...
2023-10-25 04:13:55 ET Summary Including cost saving target, we estimate a 2024 cash burn of CHF 500 million. With current cash and revenue estimates, Idorsia's top priority is to assess potential funding options. QUVIVIQ sales are not picking up as expected, leading to lower reve...
2023-10-24 09:30:11 ET More on Idorsia Idorsia's Insomniac Earnings And The Sell Signal That Won't Sleep Idorsia Ltd 2023 Q2 - Results - Earnings Call Presentation Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript Historical earnings data for Idorsia ...
2023-09-05 05:56:45 ET Summary Idorsia's Q2 2023 earnings and sales were below expectations, leading to concerns about the company's financial position. Sales growth for Idorsia's anti-insomnia drug, daridorexant, has been slow and disappointing, and no sign things will get better...
2023-07-29 12:53:06 ET Idorsia Ltd (IDRSF) Q2 2023 Earnings Conference Call July 25, 2023 09:00 AM ET Company Participants Andrew Weiss - Head of IR Jean-Paul Clozel - CEO Andre Muller - EVP & CFO Patricia Torr - VP, Head of US Finance & Infrastructur...
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...